Compare DERM & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | ANIK |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.9M | 200.9M |
| IPO Year | 2021 | 1996 |
| Metric | DERM | ANIK |
|---|---|---|
| Price | $7.11 | $15.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $12.67 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 338.9K | 61.5K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.72 | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | $61,858,000.00 | ★ $112,819,000.00 |
| Revenue This Year | $39.72 | $5.98 |
| Revenue Next Year | $63.24 | $7.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $7.90 |
| 52 Week High | $9.56 | $16.24 |
| Indicator | DERM | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 58.85 |
| Support Level | $7.00 | $13.88 |
| Resistance Level | $7.69 | $15.93 |
| Average True Range (ATR) | 0.44 | 0.46 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 86.21 | 89.66 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.